Onyx and Eli Lilly Expand Their Research Alliance on BRCA1
RICHMOND, Ca--Onyx Pharmaceuticals has announced an extension and expansion of its research alliance with Eli Lilly focusing on BRCA1, the gene linked to increased risk of breast and ovarian cancer. Lilly has exclusive rights to the BRCA1 gene by license from Myriad Genetics, Inc.
RICHMOND, Ca--Onyx Pharmaceuticals has announced an extensionand expansion of its research alliance with Eli Lilly focusingon BRCA1, the gene linked to increased risk of breast and ovariancancer. Lilly has exclusive rights to the BRCA1 gene by licensefrom Myriad Genetics, Inc.
The collaboration, originally begun in May 1995, aims to understandthe role of BRCA1-related pathways in breast cancer and to identifyproteins that interact with the gene that could be used to developtherapeutics.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
